Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 5/20 | 0.64 |
| ▸ | CTSS | P25774 | 5/20 | 0.64 |
| ▸ | CTSK | P43235 | 5/20 | 0.64 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223759 | 0.90 | CTSB (0.54) | CTSBCTSSCTSKHRH3ALDH1A1 | |
| SCHEMBL8218593 | 0.89 | CTSB (0.70) | CTSBCTSSCTSKOPRL1HRH3 | |
| SCHEMBL8224238 | 0.88 | CTSB (0.51) | CTSBCTSSCTSKOPRL1HRH3 | |
| SCHEMBL347518 | 0.86 | CTSS (0.70) | CTSBCTSSCTSKOPRL1 | |
| SCHEMBL12237384 | 0.86 | CTSB (0.66) | CTSBCTSSCTSKOPRL1HRH3 | |
| SCHEMBL347010 | 0.85 | CTSB (0.89) | CTSBCTSSCTSK | |
| SCHEMBL347517 | 0.85 | CTSB (0.64) | CTSBCTSSCTSKOPRL1GAA | |
| SCHEMBL8223886 | 0.84 | CTSB (0.53) | CTSBCTSSCTSKHRH3CYP2D6 | |
| SCHEMBL8226527 | 0.83 | CTSB (0.79) | CTSBCTSSCTSKOPRL1HRH3 | |
| SCHEMBL8223388 | 0.82 | CTSB (0.70) | CTSBCTSSCTSKGAACALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2520568-A1 | Spirocyclic nitriles as inhibitors of protease | SANOFI (FR) | 2012-11-07 | — | — | EP | disclosed |
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| WO-2007137738-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | CTSB 31/4885CTSS 24/4885CTSK 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.